Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Investigation of the role of neutralizing antibodies against bevacizumab as mediators of tachyphylaxis.

× No keyword cloud information.

17 in total

Review 1. Emerging therapeutic approaches in the management of retinal angiogenesis and edema.

Authors: An Truong; Tien Y Wong; Levon M Khachigian
Journal: J Mol Med (Berl) Date: 2010-12-18 Impact factor: 4.599

2. Tachyphylaxis during ranibizumab treatment of exudative age-related macular degeneration.

Authors: Sibel Doguizi; Sengul Ozdek; Selcen Yuksel
Journal: Int J Ophthalmol Date: 2015-08-18 Impact factor: 1.779

3. Induction of vascular endothelial growth factor receptor expression in human umbilical vein endothelial cells after repeated bevacizumab treatment in vitro.

Authors: Ji Eun Lee; Jin Young Kim; Jae Ho Jung; Dong Hoon Shin; Sung Who Park
Journal: Int J Ophthalmol Date: 2017-07-18 Impact factor: 1.779

4. Tachyphylaxis during treatment of exudative age-related macular degeneration with aflibercept.

Authors: Chikako Hara; Taku Wakabayashi; Yoko Fukushima; Kaori Sayanagi; Ryo Kawasaki; Shigeru Sato; Hirokazu Sakaguchi; Kohji Nishida
Journal: Graefes Arch Clin Exp Ophthalmol Date: 2019-09-03 Impact factor: 3.117

Review 5. Nanoengineering of therapeutics for retinal vascular disease.

Authors: Nivriti Gahlaut; Sandra Suarez; Md Imam Uddin; Andrew Y Gordon; Stephanie M Evans; Ashwath Jayagopal
Journal: Eur J Pharm Biopharm Date: 2015-05-28 Impact factor: 5.571

6. Coats-like Exudative Vitreoretinopathy in Retinitis Pigmentosa: Ocular Manifestations and Treatment Outcomes.

Authors: Omar Moinuddin; Sanjana Sathrasala; K Thiran Jayasundera; Kari H Branham; Emmanuel Y Chang; Cynthia X Qian; Franco M Recchia; Abigail T Fahim; Cagri G Besirli
Journal: Ophthalmol Retina Date: 2020-04-09

7. Management of neovascular age-related macular degeneration in clinical practice: initiation, maintenance, and discontinuation of therapy.

Authors: Pearse A Keane; Adnan Tufail; Praveen J Patel
Journal: J Ophthalmol Date: 2011-11-22 Impact factor: 1.909

8. Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD.

Authors: Heidi Fassnacht-Riederle; Matthias Becker; Nicole Graf; Stephan Michels
Journal: Graefes Arch Clin Exp Ophthalmol Date: 2014-03-11 Impact factor: 3.117

Review 9. Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration.

Authors: Paris Tranos; Athanasios Vacalis; Solon Asteriadis; Stavrenia Koukoula; Athanasios Vachtsevanos; Georgia Perganta; Ilias Georgalas
Journal: Drug Des Devel Ther Date: 2013-06-17 Impact factor: 4.162

10. Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant.

Authors: Antoine Herbaut; Franck Fajnkuchen; Lise Qu-Knafo; Sylvia Nghiem-Buffet; Bahram Bodaghi; Audrey Giocanti-Auregan
Journal: J Ophthalmol Date: 2017-08-16 Impact factor: 1.909